Evidence builds for ARBs over ACE inhibitors for CV risk

Angiotensin receptor blockers (ARBs) offer superior protection against cardiovascular events compared to ACE inhibitors, especially in patients with established disease, new data from the REACH registry shows. The observational Reduction of Atherothrombosis for Continued Health (REACH) registry followed more than 40,000 participants who were taking either treatment, mostly for existing cardiovascular disease but also for ...

Already a member?

Login to keep reading.

© 2021 the limbic